← Back to headlines
AstraZeneca Finalizes Licensing Agreement for Lung Cancer Drug Zegfrovy
Pharmaceutical giant AstraZeneca has completed a licensing deal for its lung cancer treatment Zegfrovy, marking a significant step in its oncology portfolio expansion.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Rising Oil Prices Drive Up Bond Yields and Trigger Equity Sell-Offs
59m ago
Global Bond Selloff Deepens as Yields Rise Amid Geopolitical Tensions
1h ago
N1 and CNN Confirm Expiration of Broadcasting Partnership Agreement
1h ago
U.S. Equity Markets See Midday Swings Led by Palo Alto Networks Activity
1h ago